Personal record-keeping and educational reference. 18+. The app does not recommend substances, doses or treatment, or determine whether a substance is safe, approved or appropriate for you. Consult a qualified healthcare professional about decisions involving your health.
‹ Library

Mazdutide

GLP-1 / MetabolicResearch Use Only

Also known as: IBI362, LY3305677, GLP-1/glucagon dual agonist

A GLP-1 + glucagon dual agonist in trials for weight loss with an added energy-burn component.

Dosing quick reference

research reference
Starting dose
2.5 mg once weekly
Frequency
Once weekly
Typical range
2.5–5 mg per week (advanced: 10)
Cycle
12–48 weeks
Titration (step-up)
Wk 1–4: 2.5 → Wk 5+: 5 mg
Half-life
~4–7 days (reported)
Route
Subcutaneous (research)
Common use
Metabolic and weight-management research
Common vial sizes
5 mg · 10 mg
Storage
Store lyophilized powder refrigerated (2–8°C) and protected from light; once reconstituted, keep refrigerated and use within the timeframe supported by stability data.
Stacking notes
Referenced in research as a single dual-agonist molecule; combining with other incretin agents is not standard in the literature.

Reported side effects

NauseaReduced appetiteDiarrheaGastrointestinal upset
Regulatory note: Investigational; not FDA-approved. Under clinical development (regulatory approval reported in China in some sources); not approved in Canada. Research-grade material is not for human use.
Calculate a dose →Mazdutide on The Peptide Guide →Deeper research reference: literature dose ranges, storage and handling, and where to source in Canada.

Dose figures are ranges commonly referenced in research literature, not recommendations or medical advice. Research-only labeling does not establish that a substance is safe, approved or appropriate for personal use. Consult a qualified healthcare professional about health decisions.